|
Myeloproliferative Leukemia virus oncogene (MPL) testing in Myeloproliferative Neoplasms
(MPNs) |
|
|
|
Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Myeloproliferative Leukemia virus oncogene (MPL) testing in Myeloproliferative Neoplasms
(MPNs) Lansdale: HAYES, Inc.. Genetic Testing Publication. 2013 Authors' conclusions Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) are characterized by overproduction of blood cells and include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), which have overlapping as well as distinct characteristics. MPNs are rare conditions with a prevalence of 0.79, 0.25, and 0.53 per 100,000 individuals for PV, PMF, and ET, respectively. Of these, PMF is the most severe, with an average survival of 5 years from diagnosis. In 2008, the World Health Organization (WHO) recommended criteria for diagnosing MPNs that included detection of a variant in the janus kinase 2 (JAK2) gene present in 40% to 60% of individuals with ET or PMF. In the absence of the JAK2 variant, myeloproliferative leukemia virus oncogene (MPL) variants in ET and PMF patients may be tested. The MPL gene is located on chromosome 1 at band p34. MPL variants are present in approximately 3% and 10% of ET and PMF patients, respectively, but have not been detected in patients with PV. Therefore, testing for this variant might provide a diagnostic tool to identify JAK2-negative patients who may develop ET or PMF. In addition, variants in this gene might serve as targets for drug therapy. Indexing Status Subject indexing assigned by CRD MeSH Leukemia, Myelogenous, Chronic, BCR-ABL Positives; Myeloproliferative Disorders Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000828 Date abstract record published 13/11/2013 |
|
|
|